AstraZeneca has recently launched a new global health tech business, Evinova, with the goal of streamlining and simplifying the clinical trial process. The company recognized a need in the market for these services and created Evinova to address this gap.
Operating as a separate business from its parent company, AstraZeneca, Evinova will provide global services to CROs and pharmaceutical companies to design, run, and monitor clinical trials. Customers will have access to Evinova’s technology on a revenue-based model.
Through the creation of Evinova, AstraZeneca aims to tackle the challenges and inefficiencies in the clinical trial process. By doing so, it hopes to make it easier for patients to participate and improve the overall effectiveness of trials. This new venture reflects AstraZeneca’s dedication to advancing healthcare and utilizing technology to improve drug development processes.
